Sacramento Sessions/5 of 3

Radiant Exhibits and Presents Smart Glass Measurement Solutions for Emerging Sunroof Technologies at Vehicle Displays & Interfaces

Retrieved on: 
Wednesday, August 17, 2022
Electronics, Glass, Table, Exhibition, Industry, Konica Minolta, Technology, Growth, Sun photometer, Software, Original equipment manufacturer, HUD, Method, Hud, International, Society, Scholz, Lighting, SID, Sacramento Sessions/5 of 3, Light-emitting diode, Color, Quality control, Automotive industry, Interface, Prometric, Solution, Device file, Efficiency, Ceramic, Online shopping, Radiant

REDMOND, Wash., Aug. 17, 2022 /PRNewswire-PRWeb/ -- Radiant Vision Systems, a leading provider of test and measurement solutions for automotive displays, announces that it will exhibit and lead a technical session at the SID (Society for Information Display) 29th Annual Vehicle Displays & Interfaces Symposium & Expo. The event takes place at a new location at the Sheraton Detroit Novi Hotel on September 27 and 28, 2022. Radiant will exhibit solutions for evaluating the visual quality of head-up displays (HUD) and other automotive display integrations from tables 601 & 603 in the exhibit hall and will present a paper during Session 5: Display Metrology on Wednesday, September 28, beginning at 10:40 A.M. local time.

Key Points: 
  • Vehicle Displays & Interfaces has provided the leading forum for automotive display technology for nearly 30 years.
  • Topics of this year's event include automotive market trends, touch interfaces, HUDs, component & substrate innovations, lighting, and display measurement.
  • However, the size of sunroof panels, intricacies of their etched patterns, and glass curvature make this emerging inspection application difficult to address using traditional display measurement technologies.
  • Throughout the event, Radiant will also demonstrate its solutions for automotive display testing from tables 601 & 603 as part of the Vehicle Displays & Interfaces exhibition.

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 10, 2021
Breakthrough therapy, PD-1, Patient, AE, National Medical Products Administration, U.S. Securities and Exchange Commission, Forward-looking statement, Neutropenia, NEW, Breast cancer, Pain, ANC, Toxicity, Breast, NASDAQ, TAC, Docetaxel, Doxorubicin, Haematopoiesis, APC, Bone pain, GLOBE, CIN, HSPC, Cancer, Large-cell lung carcinoma, Overalls, Cyclophosphamide, Sacramento Sessions/5 of 3, Research, NSCLC, Company, EGFR, Safety, Anxiety, Stanford University School of Medicine, Knowledge, Therapy, Data analysis, B cell, Quality of life, Â, Pegfilgrastim, Survival, Form 20-F, AES, Medicine, Pharmaceutical industry, Medical imaging, Risk management, Health insurance

Our goal has always been to create a better cancer treatment experience for these patients by alleviating some of the issues that can occur with CIN.

Key Points: 
  • Our goal has always been to create a better cancer treatment experience for these patients by alleviating some of the issues that can occur with CIN.
  • We look forward to continuing to study how plinabulin can potentially make a difference in this indication.
  • The depth of ANC nadir was statistically significantly correlated with bone pain scores; TAC+Peg vs TAC+Peg+Plin, p=0.019.
  • TAC should be reevaluated for patients with early-stage breast cancer in light of the improved outcomes seen with the addition of plinabulin and pegfilgrastim.